A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer

被引：7

作者：

Puglisi, Fabio ^{[1
]}

Bisagni, Giancarlo ^{[2
]}

Ciccarese, Mariangela ^{[3
]}

Fontanella, Caterina ^{[1
]}

Gamucci, Teresa ^{[4
]}

Leo, Luigi ^{[5
]}

Molino, Annamaria ^{[6
]}

Silva, Rosa Rita ^{[7
]}

Marchetti, Paolo ^{[8
,9
]}

机构：

[1] Univ Udine, Dept Med & Biol Sci, Udine, Italy

[2] Azienda Osped ASMN, Dept Oncol, Oncol Unit, Ist Ricovero & Cura Carattere Sci, Reggio Emilia, Italy

[3] Vito Fazzi Hosp, Dept Med Oncol, Lecce, Italy

[4] ASL Frosinone, Med Oncol Unit, Frosinone, Italy

[5] Azienda Osped Colli, Oncol Unit, Naples, Italy

[6] Univ Verona, Verona, Italy

[7] ASUR Marche AV2 Fabriano, Med Oncol Unit, Fabriano, Italy

[8] Sapienza Univ Rome, Med Oncol, St Andrea Hosp, Rome, Italy

[9] IDI IRCCS, Rome, Italy

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 22期

关键词：

angiogenesis; bevacizumab; breast cancer; PROGRESSION-FREE SURVIVAL; PHASE-III TRIAL; CONTAINING THERAPY; OPEN-LABEL; NEOADJUVANT CHEMOTHERAPY; PLUS BEVACIZUMAB; TARGETED THERAPIES; AND/OR BEVACIZUMAB; LOCALLY RECURRENT; CLINICAL-PRACTICE;

D O I：

10.2217/fon-2016-0295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To gain consensus on the role of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer, a panel of expert oncologists experienced in treating patients with metastatic breast cancer in Italy participated in a Delphi consensus study. The panel reached a full consensus on the efficacy of bevacizumab plus paclitaxel and the clinical meaningfulness of the progression-free survival benefit compared with paclitaxel alone, despite the lack of an overall survival effect in clinical trials. The participants agreed that real-world data support the effectiveness and well-defined safety profile of the regimen. Views on the use of bevacizumab plus paclitaxel in specific patient populations were not unanimous and clinical judgment remains important. Nevertheless, a high level of agreement was reached.

引用

页码：2589 / 2602

页数：14

共 50 条

[31] Markov Model and Cost-Effectiveness Analysis of Bevacizumab in HER2-Negative Metastatic Breast Cancer
Refaat, Tamer
Choi, Mehee
Gaber, Germaine
Kiel, Krystyna
Mehta, Minesh
Gradishar, William
Small, William, Jr.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (05): : 480 - 485
[32] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
Audrey Petitjean
Jayne Smith-Palmer
William Valentine
Bertrand Tehard
Stephané Roze
BMC Cancer, 19
[33] Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
Petitjean, Audrey
Smith-Palmer, Jayne
Valentine, William
Tehard, Bertrand
Roze, Stephane
BMC CANCER, 2019, 19 (1)
[34] Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
Lam, S. W.
de Groot, S. M.
Honkoop, A. H.
Jager, A.
ten Tije, A. J.
Bos, M. M. E. M.
Linn, S. C.
van den Bosch, J.
Kroep, J. R.
Braun, J. J.
van Tinteren, H.
Boven, E.
EUROPEAN JOURNAL OF CANCER, 2014, 50 (18) : 3077 - 3088
[35] Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
Chan, A.
Miles, D. W.
Pivot, X.
ANNALS OF ONCOLOGY, 2010, 21 (12) : 2305 - 2315
[36] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients
Jacquet, E.
Lardy-Cleaud, A.
Pistilli, B.
Franck, S.
Cottu, P.
Delaloge, S.
Debled, M.
Vanlemmens, L.
Leheurteur, M.
Guizard, A. V.
Laborde, L.
Uwer, L.
Jacot, W.
Berchery, D.
Desmoulins, I.
Ferrero, J. M.
Perrocheau, G.
Courtinard, C.
Brain, E.
Chabaud, S.
Robain, M.
Bachelot, T.
EUROPEAN JOURNAL OF CANCER, 2018, 95 : 93 - 101
[37] Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Vrdoljak, E.
Marschner, N.
Zielinski, C.
Gligorov, J.
Cortes, J.
Puglisi, F.
Aapro, M.
Fallowfield, L.
Fontana, A.
Inbar, M.
Kahan, Z.
Welt, A.
Levy, C.
Brain, E.
Pivot, X.
Putzu, C.
Gonzalez Martin, A.
de Ducla, S.
Easton, V.
von Minckwitz, G.
ANNALS OF ONCOLOGY, 2016, 27 (11) : 2046 - 2052
[38] Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study
Xu Bing-he
Jiang Ze-fei
Shen Zhen-zhou
Guan Zhong-zhen
Chen Zheng-dong
Cheng Ying
Zheng Hong
Jiang Jun
Wang Xiao-jia
Tong Zhong-sheng
Qin Shu-kui
Luo Yi
Yao Min
Wang Li-wei
He Jing
CHINESE MEDICAL JOURNAL, 2012, 125 (05) : 764 - 769
[39] Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
Dieras, Veronique
Wildiers, Hans
Jassem, Jacek
Dirix, Luc Y.
Guastalla, Jean-Paul
Bono, Petri
Hurvitz, Sara A.
Goncalves, Anthony
Romieu, Gilles
Limentani, Steven A.
Jerusalem, Guy
Lakshmaiah, K. C.
Roche, Henri
Sanchez-Rovira, Pedro
Pienkowski, Tadeusz
Segui Palmer, Miguel Angel
Li, Ai
Sun, Yu-Nien
Pickett, Cheryl A.
Slamon, Dennis J.
BREAST, 2015, 24 (03): : 182 - 190
[40] First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab
Fujii, Teruhiko
Takahashi, Hiroki
Matsubayashi, Roka Namoto
Inoue, Yuka
Takenaka, Miki
Toh, Uhi
Kage, Masayoshi
Yamana, Hideaki
Shirouzu, Kazuo
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 583 - 593

← 1 2 3 4 5 →